New Jersey S4222 aims to improve access to lower-cost generic and biosimilar drugs.
New Jersey S4222 seeks to enhance access to lower-cost generic and biosimilar drugs by requiring managed care organizations and vendors to make these drugs available on their formularies with more favorable cost sharing. The bill mandates that if a biosimilar is available, it should be prescribed to covered persons or enrollees who have not previously been treated with the prescribed brand drug.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.